Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

8 Feb 2021

Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller

La Jolla, California–(Newsfile Corp....

By Microdose

Press Releases

8 Feb 2021

Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing

Acquisition expands Numinus’ presence while improving psychedelic-assisted therapy landscape in Canada VANCOUVER, BC, Feb....

By Microdose

Press Releases

5 Feb 2021

Numinus Engages Native Ads Inc. for Digital Media Services

VANCOUVER, BC, Feb....

By Microdose

Press Releases

5 Feb 2021

Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds

Toronto, Ontario–(Newsfile Corp....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

4 Feb 2021

Entheon Biomedical Hires ClearTV Executive as VP of Digital Experience Entertainment Veteran Jonna Birgans to Oversee Digital and VR Content Development

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

4 Feb 2021

Cybin Announces Closing of Upsized Bought Deal Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ Official ReleaseCybin Inc....

By Microdose

Press Releases

4 Feb 2021

Psyched Wellness Provides Update on Antioxidant and Anti-Inflammatory Study of Muscimol

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

3 Feb 2021

Aion Therapeutic Grants Stock Options; Announces Management Change

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

3 Feb 2021

REPEAT – Pure Extracts Announces Submission for Class 1 Natural Product Number (NPN)

VANCOUVER, British Columbia, Feb....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.